Heron Therapeutics (HRTX) Reports FDA Approval of SUSTOL - StreetInsider.com

Channel NewsAsia

Heron Therapeutics (HRTX) Reports FDA Approval of SUSTOL StreetInsider.com Heron Therapeutics, Inc. (NASDAQ: HRTX), today announced that the U.S. Food and Drug Administration (FDA) has approved SUSTOL® (granisetron) extended-release injection. SUSTOL is a serotonin-3 (5-HT3) receptor antagonist indicated in combination ... UPDATE 1-FDA approves Heron's therapy for chemotherapy-induced nauseaReuters FDA approves Heron's therapy for chemotherapy-induced nauseaReuters UK all 5 news articles »

Heron Therapeutics (HRTX) Reports FDA Approval of SUSTOL - StreetInsider.com
Read More